Sipuleucel-T: An Autologous Cellular Immunotherapy for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Dr Andy Stubbs the Senior Medical Director at Dendreon joined us at the World Vaccine Congress Washington to talk to us about Sipuleucel-T, an autologous Cellular Immunotherapy for patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

Dr Stubbs guided us through the following:

  • Introduction to prostate cancer
    • Natural History of Prostate Cancer
  • Overview of sipuleucel-T & Pre-clinical rationale
    • Sipuleucel-T: Designed to Activate a
      Patient's Immune System
    • Pre-Clinical Rationale
  • Clinical Development of sipuleucel-T
    • Phase I/II Trials: Immune Effects
    • Phase I/II Trials: Clinical Effects
    • Phase 3 Randomized, Double Blind, Placebo- Controlled Trials, Studies D9901 and D9902A
    • Sipuleucel-T Overall 3-Year Survival, ITT Study D9901
    • IMPACT Phase 3 Study (D9902B)
    • IMmunotherapy for Prostate AdenoCarcinoma Treatment
    • IMPACT Overall Survival: Primary Analysis (331 Events)
    • Consistency Across Phase 3 Studies
    • Time to Objective Disease Progression (ODP)
    • Reconciling Lack of Effect on Time to Objective Disease Progression in CRPC?
    • Proposed Impact of Immunotherapy on Disease Kinetics
    • Adverse Events More Commonly1 Reported in Sipuleucel-T Group
  • Immune response to sipuleucel-T
    • Sipuleucel-T Laboratory/Clinical Correlations
    • CD54 Upregulation Potency Assay for APCs
  • Lessons learned

Download the whole presentation here.

Comments 2

Leave a Reply

Your email address will not be published. Required fields are marked *